"Idiopathic" mental retardation and new chromosomal abnormalities by Galasso, Cinzia et al.
REVIEW Open Access
“Idiopathic” mental retardation and new
chromosomal abnormalities
Cinzia Galasso, Adriana Lo-Castro
*, Nadia El-Malhany, Paolo Curatolo
Abstract
Mental retardation is a heterogeneous condition, affecting 1-3% of general population. In the last few years, several
emerging clinical entities have been described, due to the advent of newest genetic techniques, such as array
Comparative Genomic Hybridization. The detection of cryptic microdeletion/microduplication abnormalities has
allowed genotype-phenotype correlations, delineating recognizable syndromic conditions that are herein reviewed.
With the aim to provide to Paediatricians a combined clinical and genetic approach to the child with cognitive
impairment, a practical diagnostic algorithm is also illustrated. The use of microarray platforms has further reduced
the percentage of “idiopathic” forms of mental retardation, previously accounted for about half of total cases. We
discussed the putative pathways at the basis of remaining “pure idiopathic” forms of mental retardation, highlight-
ing possible environmental and epigenetic mechanisms as causes of altered cognition.
Introduction
Mental retardation (MR) is a variable, heterogeneous
manifestation of central nervous system dysfunctions,
occurring in 1-3% of general population [1]. MR repre-
sents one of the most frequently diagnosed disabling
condition in our society, and a lifelong disability charac-
terized by impairment of cognitive and adaptive skills.
The aetiology is very heterogeneous and, unfortu-
nately, in about than one-half of cases the cause of MR
is still elusive [2]. Anything that damages and interferes
with the growth and maturation of the brain can lead to
MR, and this might happen before, during or after the
birth of the child (complications of pregnancy/birth,
toxics, malnutrition, trauma, infections, understimula-
tion). Moreover, genetically determined MR aetiology
(comprising chromosomal aberrations, single-gene disor-
ders, and other genetic conditions) account by itself for
17 to 41% of cases, depending of the different techni-
ques of analysis [2].
Several syndromes (such as Down, Rett syndrome, and
other well known conditions) should be easily suspected
because of their association to specific dysmorphisms,
behavioural peculiarities, and multiple congenital
abnormalities. However, a consistent percentage of
children with genetic MR do not present a recognizable
phenotype striking of a well-recognizable syndrome.
With the advent of novel genetic techniques, several
new cryptic chromosomal aberrations have been discov-
ered in last few years [3,4], and a consistent number of
MR cases, previously considered “idiopathic” forms, are
now classified as syndromic conditions with clinical
recognizable phenotypes [5]. Microarrays techniques
(such as array-Comparative Genomic Hybridization,
array-CGH) revealed submicroscopic aberrations in
5-17% of MR patients with normal results from prior
conventional cytogenetic testing [6], and higher-density
platforms (such as Single-Nucleotide Polymorphism
array, SNP array) provided to increase diagnosis in
about 6% of cases evaluated by lower-density oligonu-
cleotide arrays [2].
Determining a specific etiologic diagnosis is central to
understand the nature of the problem, providing
answers to questions regarding prognosis, recurrence
risks, directing specific therapies, and achieving mean-
ingful inclusion of individuals with disability into
society.
Search strategy and selection criteria
Information in this review is mainly based on peer-
reviewed medical publications of syndromic conditions
from 2005 to 2010 (PubMed). Selection criteria are the
novelty and importance of studies, and their relevance
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mental retardation”, “mental retardation”, “cryptic chro-
mosomal abnormalities”, and “array-CGH”. Only articles
published in English were reviewed. All articles were
read by the authors and references were reviewed to
identify any additional relevant studies.
Clinical Approach
The clinical approach of a child with MR is a key moment
to provide a definitive diagnosis, and requires some
exhaustive and comprehensive evaluations of the patient.
First of all, a three-generation pedigree should be
done, and a detailed pre-, peri- and postnatal history is
mandatory. A dysmorphic child may be at risk from the
stress of birth, and later delay may be erroneously
attributed to birth injury [7]. A careful developmental
history, with emphasis on milestones, formal assess-
ments and behavior, is also required. Medical records
should be sought or requested to validate any diagnosis
of malformations. An accurate EEG study and/or brain
MRI are sometimes sufficient to suspect several well-
known and relatively common disorders (such as Rett
syndrome, Angelman syndrome, neurocutaneous syn-
dromes, etc.) [8,9]. The degree of MR is an important
indicator: the so called “chromosomal” phenotype,
which is well known to accompany larger aberrations, is
frequently characterized by moderate-severe MR asso-
ciated to one or more of major signs, including congeni-
tal malformations. The behavioral phenotype is also
distinctive for several well-known syndromic conditions,
such as Williams syndrome, Angelman syndrome, Pra-
der-Willi syndrome, and so on [10].
Finally, the physical examination of the child is crucial
for a “gestaltic” diagnosis: sometimes the syndromic con-
dition can be instantaneously suspected by recognition of
“handles”, based on past clinical experience. Hovewer,
phenotypic expression among patients with well-recog-
nized microdeletion or microduplication syndromes may
vary on the basis of different sizes of genomic alterations,
and of individual differences in the rest of the genome.
Unfortunately, in many cases the MR is the unique and
unspecific sign present in the patient, with lack of major
hallmarks. When present, minor anomalies of the face
(such as hypo-hypertelorism, unusual ear conformation,
multiple hair whorls, etc.),h a n d s ,g e n i t a l i a ,a n ds k i n
should be noted and supplemented by objective measure-
ments. Abnormalities in head size, growth parameters,
and neurologic signs should be carefully investigated.
The phenotype can also vary during the time, it
should be useful to collect photos and/or videos of
patients at different ages, also because the amount of
controls in our experience often affects the probability
to define the etiology.
Genetic Approach
Genetic abnormalities are the most common identifiable
cause of unexplained MR [11], but conventional karyo-
typing is unable to detect imbalances smaller than about
3-5 Mb [12]. Smaller chromosomal abnormalities can be
identified with fluorescent in situ hybridization (FISH)
or multiplex ligation-dependent probe amplification
(MLPA) techniques, confirming a clinical suspicion of
well-known microdeletion/microduplication syndromes
(i.e. Williams syndrome, Velocardiofacial/DiGeorge syn-
drome, etc.) or analysing subtelomeric regions of all
chromosomes. The combined analysis of karyotype and
subtelomeric regions, using FISH or other molecular
techniques, have allowed the detection of chromosome
abnormalities in about 5-10% of these patients [11,12].
The newer chromosome microarray or comparative
genomic hybridization technique (array-CGH) is an effi-
cient manner to approach a case of MR. It does not
require an expert clinician to suspect a specific diagno-
sis, and may cover the entire genome or targets known
pathologic loci in an unique test, identifying deletions
and/or duplications with a higher degree of sensitivity.
This new technique has revealed submicroscopic chro-
mosome aberrations in MR patients with normal results
from prior cytogenetic analyses with detection rates as
5-20% [6,13]. However, array-CGH is incapable of
detecting balanced rearrangements of chromosomal
material (including reciprocal translocations and inver-
sions), which are expected to occur in about 0.75% of all
MR patients [14]. Moreover, the interpretation of micro-
array data in MR is complicated by the discovery of
areas of DNA segment longer than 1 kb, with a variable
copy number compared with a normal reference gen-
ome, called Copy Number Variations (CNVs) [15].
CNVs are associated to a pathological phenotype when
one or more dosage-sensitive genes inside the rear-
ranged region are altered. However, CNVs are not con-
sidered pathologic in all cases, because they appear to
be conserved across primate species and may be respon-
sible of individual diversity and human evolution. In a
single individual, it is possible to detect even > 1000
non-pathological common CNVs [16], needing the com-
parison with unaffected control cohorts and parental
tests [17]. The detection of a relatively large, rare, de
novo CNV in an affected patient is strongly indicative of
pathological significance, and is present in about 10% of
cases of MR with normal chromosome analysis [1,18].
CNVs should be considered causative of the condition
when: 1) CNVs overlap with regions known to cause
well delineated MR syndromes; 2) CNVs include the cri-
tical region of a syndrome or causative genes; 3) the
phenotype of the patient is consistent with the syn-
drome’s features [2].
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A possible diagnostic algorithm which can be useful in
the evaluation of a child with unexplained MR and sus-
pected genetic condition [8,9] is illustrated in the Figure
1. After a detailed anamnesis assessed by three-genera-
tions pedigree analysis, a comprehensive cognitive, beha-
vioral and physical examination (clinical and
instrumental) is mandatory. Depending on the suspected
or not-suspected diagnosis, the work-up of a patient can
follow two different pathways, guiding to decisions
regarding laboratory testing and imaging studies. On the
basis of the presence of dysmorphic signs and/or major
abnormalities (such as multiple congenital defects),
high-resolution karyotype, fragile-X DNA analysis, tar-
geted FISH/MLPA, or metabolic tests should be consid-
ered. EEG and/or MRI are also useful. Finally, array-
CGH is indicated when above-mentioned tests are
negative.
When the child has an apparently normal phenotype,
after high-resolution karyotype, fragile-X molecular
tests, EEG, and MRI studies, array-CGH analysis should
be directly performed to exclude a cryptic chromosomal
aberration.
Chromosomal Abnormalities
Recent developments in array technology have strongly
changed the genetic approach to MR, combining the
whole-genome analysis of karyotyping technology and
the targeted high-resolution of FISH test. Genomic
microarrays have a resolution 10-10000 times higher
than that of conventional karyotyping, identifying rare,
de novo, submicroscopic interstitial imbalances or CNVs
in about 5-20% of cases of idiopathic MR and multiple
congenital abnormalities, depending on the clinical
selection of patients [1,12]. The increased identification
of novel microdeletion/microduplication syndromes is
based on an accurate genotype-phenotype correlation,
characterized by the association of similar chromosomal
aberrations and overlapped clinical presentations
between affected patients.
The ability to recognize pathological gestalts and/or
behaviors has already led to a significant improvement
Figure 1 Diagnostic algorithm proposed for unexplained MR cases of suspected genetic origin. Array-CGH = array-Comparative Genome
Hybridization; FISH: Fluorescent In Situ Hybridization; Fra-X: Fragile × syndrome molecular analysis; HRK: high-resolution karyotype; microdel/dup:
microdeletion/microduplication; MLPA: Multiplex Ligation-dependent Probe Amplification.
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example of relatively common, novel well-delineated
syndromes are discussed in this review. Salient phenoty-
pical traits of each syndrome are also synthesized in
Additional file 1.
1p36 microdeletion syndrome
Monosomy 1p36 is a well-described contiguous genes
syndrome, considered as the most common terminal
deletion observed in humans, accounting for 0.5-1.2% of
idiopathic MR [19,20]. Dysmorphisms are very remark-
able and distinctive of this condition: microcephaly,
large and late closing anterior fontanel, tower skull, pro-
minent forehead, straight eyebrows, deep-set eyes, flat
nasal bridge with midface hypoplasia, abnormal ears,
brachydactyly/camptodactyly, and short feet (Figure 2a,
b). Severe hypotonia, seizures, oropharyngeal dysphagia,
and heart defects are also common [20]. MR of any
degree, mostly moderate to severe, is present in all indi-
viduals, associated to a severe speech impairment and
poor coordinated movements control [19]. Subtelomeric
FISH analysis, targeted FISH analysis of chromosome 1
and/or array-CGH are needed to detect the 1p36 micro-
deletion. This syndrome should be considered in a
young child with above-mentioned dysmorphisms, psy-
chomotor delay and hypotonia, in particular when the
language is poor or absent, and self-injuring behaviors,
stereotypies, and hyperactivity are present.
2q23.1 microdeletion syndrome
This new syndrome has been identified by a-CGH in
patients with severe MR and severe speech impairment,
associated with microcephaly, coarse face, short stature,
and epilepsy [21]. Frequently, the phenotype of syn-
drome includes stereotypic behaviors, altered sleep pat-
tern and a broad-based gait, leading to the clinical
impression of Angelman, Rett or Smith-Magenis syn-
dromes [22]. Haploinsufficiency of MBD5 or EPC2
genes, included in the deleted genomic region, seems to
be responsible of the typical phenotype [22,23].
2q37 deletion syndrome
Del(2q37) syndrome is now a well recognized disease,
characterized by facial dysmorphic features (Figure 2c),
developmental delay, hypotonia, epilepsy in 25% of
cases, and major anomalies in about 30% [24,25].
Psychiatric conditions are frequently associated with
del(2q37). Autism spectrum disorders is present in
24-35% of del(2q37) cases, but also severe speech delay,
stereotypic movements, aggressive behavior, attention-
deficit/hyperactivity disorder (ADHD), and obsessive-
compulsive disorder are commonly observed [24]. In a
child with MR and these neuropsychiatric disorders, the
presence of facial dysmorphic traits and congenital
defects, variably associated with short stature, obesity,
brachydactyly, eczema, and hypotonia, should be consid-
ered highly suggestive of del(2q37). High resolution kar-
yotype, FISH/MLPA or aCGH analyses are useful for
diagnosis [25].
7q11.3 microduplication syndrome
Williams-Beuren syndrome (WBS), caused by deletion
of a 1.4-1.5 Mb region located at 7q11.23, is among the
most well-characterized microdeletion syndrome, but
the reciprocal microduplication of this genomic region
is less well described. The clinical phenotype of 7q11.23
microduplication seems to vary among patients, ranging
from mild to severe MR [26]. The neurobehavioral phe-
notype is the opposite of WBS: instead of fluent expres-
sive language, dup 7q11.23 patients show severe speech
delay and only mildly impaired visuospatial skills [27].
Mild facial dysmorphisms (short philtrum, thin lips, and
straight eyebrows), an increased incidence of heart
defects, diaphragmatic hernia, cryptorchidism, and non-
specific MRI brain abnormalities should orientate the
clinician to make diagnosis [28].
15q13.3 microdeletion syndrome
The overall incidence of this aberration is about 0.3% of
patients with “idiopathic” MR, considering it comparable
to William and Angelman syndromes [29]. MR ranges
from mild to moderate, and 15q13.3 deletion has also
been recently associated to a higher predisposition to
autism spectrum disorders, schizophrenia, other psychia-
tric disorders, and idiopathic generalized epilepsy or
EEG abnormalities [30]. The syndrome has a highly
variable intra- and inter-familial phenotype, with mild
facial dysmorphisms, including hypertelorism, upslanting
palpebral fissures, prominent philtrum with full everted
l i p s ,a n ds h o r ta n d / o rc u r v e df i f t hf i n g e ra n ds h o r t
fourth metacarpals [31].
16p11.2 microdeletion syndrome
Microdeletion at 16p11.2 has recently been associated with
autism in two different studies [32,33], but this syndrome
is characterized by a variable phenotype, ranging from
normal intelligence and mild dysmorphisms to severe cog-
nitive impairment and minor/major congenital abnormal-
ities. Facial features are characterized by flat and
hypotonic facies, deep-set eyes, low-set and posteriorly
rotated ears, and thin upper lip. Frequent ear infections,
orofacial clefting, heart defects, and minor hand/foot
anomalies have been described [34,35]. Expressive lan-
guage disorder, dyslexia, and ADHD are also frequent [36].
17q21.31 deletion syndrome
This novel syndrome seems to have a prevalence of 1 in
16 000 individuals, and to be underestimated. In all
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from an early age, associated to hypotonia with poor
sucking and slow feeding [37]. Facial dysmorphisms
include long face high/broad forehead, upslanting pal-
pebral fissures, anteverted and large ears, and the typi-
cally “tubular” or “pear shaped” nose with bulbous tip.
Abnormality of hair pigmentation and texture, and in
general, of ectodermal structures, are also observed [38].
The facial gestalt changes with age: in infancy the facial
hypotonia, with an open mouth appearance, is predomi-
nant. With increasing age, the face becomes elongated
and the tubular or pear shape form of the nose is more
pronounced. In addition, patients with del 17q21.31 may
have long fingers, nasal speech, and friendly disposition
Figure 2 Pictures of three patients with mental retardation and dysmorphisms with a genetic diagnosis. a) de novo 1p36 deletion in a
22 months old girl; b) The same patient at 3 years of age. Note prominent forehead, very straight eyebrows, epicanthus, deep-set eyes, flat
nasal bridge, and thin lips; c) de novo 2q37.1 deletion in a 7 years old girl. Note bushy eyebrows, horizontal palpebral fissures, flat nasal philtrum
with prominent columella, thin upper lip, high palate, microretrognatia, and rather asymmetrical ears; d) 22q11.2 duplication inherited from
affected mother, in a 4 years old girl. Note high forehead, sparse eyebrows, short and downslanting palpebral fissures, hypertelorism, bulbous
nose, pronounced philtrum, fullness of jowls, and large and simplified ears with protruding lobes.
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lepsy, hypermetropia, pectus excavatum, congenital
heart defects, kidney and urologic anomalies, dislocation
of the hips, and spinal deformities [38].
22q11.2 microduplication
Microduplication of 22q11.2 (dup22q11.2) has recently
emerged as a new chromosomal syndrome (Figure 2c).
Dup22q11.2 represents the reciprocal duplication of
region deleted in Di George/Velocardiofacial syndrome
(DG/VCFS), due to misalignment of low-copy repeats in
this band. Although this syndrome shares features with
DG/VCFS (heart defects, velopharyngeal insufficiency with
or without cleft palate, hypernasal speech, and urogenital
abnormalities), a clear genotype-phenotype correlation is
not yet established [39]. Individuals with dup22q11.2 show
normal intelligence or cognitive impairment of any
degrees. Neurological and psychiatric disorders, including
speech delay, learning disabilities, motor impairment,
aggressiveness, anxiety, depression, autisms, ADHD, oppo-
sitional-defiant disorder, obsessive traits, and social inter-
action problems are frequently associated [39,40]. The
microduplication is only detectable by interphase FISH,
MLPA or a-CGH analyses, and the genetic test is recom-
mended in children with central hypotonia, severe speech
delay, learning disabilities/cognitive impairment, or psy-
chiatric disorders including autism [40].
Conclusions
It is generally assumed that severe forms of MR are
thought to be due to larger chromosomal abnormalities
or defects in single genes, in the majority of cases
detectable with specific genetic tests. Paediatricians
should be alerted by the presence of MR of unexplained
origin associated with altered auxological parameters,
multiple congenital defects, neurological and psychiatric
signs, and/or minor dysmorphisms. However, many chil-
dren who have MR and dysmorphisms often do not
have major malformations, simply having an appearance
that is unusual compared with the general population,
and out of keeping with that of unaffected close rela-
tives. In particular, mild forms of MR often lack sugges-
tive clinical “handles”, resulting from the interaction of
multiple genes and non-genetic factors [41]. Despite the
introduction of high-resolution platforms has facilitated
the identification of emerging microdeletion/microdupli-
cation syndromes, in mild forms of MR making an etio-
logical diagnosis is still very difficult. The quote of
“idiopathic” forms of MR account for about half of total
cases, probably due to combination of multigenic and
environmental causes. The developing brain is more
susceptible to insults by toxic agents than adults,
because during the prenatal life several complex stages
of organization and maturation must develop in a tightly
controlled time. Moreover, the blood-brain barrier is not
completely formed until the sixth month of intrauterine
life, leading the developing brain exposed to toxins [42].
In addition, a mutation in a single gene (responsible a
for genetic syndrome) may lead to epigenetic dysregula-
tion [43], influencing transcription and/or silencing
other genes. Epigenetic mechanisms play a central role
in higher-order brain functions, influencing the capacity
to modify, reorganize and remodel synaptic plasticity
and networks during learning and memory formation,
and in response to injury. Several well-known syn-
dromes are caused by disrupted epigenetic mechanisms,
such as Rett syndrome, and fragile × syndrome [44]. In
these and others genetic conditions, as well as in envir-
onmental MR -associated disorders (e.g. fetal alcohol
spectrum disorders or lead exposure) reduced dendritic
complexity, and significant differences in dendritic spine
numbers and morphological spine types have been
observed [43,44]. However, epigenetic mechanisms are
dynamic and potentially reversible, providing new phar-
macological approaches to treat neurodevelopmental
disorders. DNA-demethylating drugs and HDAC inhibi-
tors are two promising examples of targeted epigenetic
drugs [43]. The implementation of the so called “next
generation sequencing” technologies (that allow the ana-
lysis of whole-genomes, transcriptomes and interac-
tomes) could lead to detect single base mutations and
structural variations, further broadening the possibility
of diagnosis in “idiopathic” cases of MR. Understanding
the pathological pathways underlying unexplained forms
of MR represent a future challenge to increase both pre-
vention and possible therapies.
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